Max Gelman

Neumora fail: First Phase 3 for depression drug is an unequivocal miss. The company is still running two other identical Phase 3 trials, @ky_lahucik has the latest. $NMRA -79% endpts.com/neumoras-major…

Vanza triple PR: news.vrtx.com/news-releases/…

FDA approved Vertex's "vanza triple" formulation for cystic fibrosis, and new mutations for Trikafta. Both come with boxed warnings news.vrtx.com/news-releases/…

Now updated and with new version of the chart! $NVO $LLY $VKTX $RHHBY

This will be one to watch. Sorriso says it has figured out how to make an orally-administered antibody, and is claiming success in Phase 1b study in ulcerative colitis. @MaxGelman has the details for @endpts - endpts.com/sorriso-claims…

Sarepta has a long & controversial history of getting Duchenne drugs OK’d w/accelerated approval. Now it will try in more rare diseases. "We will apply that same focus and creative energy and patient-mission approach to these therapies," the CEO said. endpts.com/sarepta-arrowh…

The FDA has approved BridgeBio's rare heart disease drug, notably including mortality on the label. BridgeBio will brand the drug as Attruby, and it will cost about $245K per year. $BBIO endpts.com/fda-approves-b…

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try endpts.com/could-trump-an…

Sage reports Phase 2 failure in Huntington's disease, ends drug's development $SAGE endpts.com/sage-reports-p…

NEW: Me and @RLCscienceboss took a look at how Sage's upcoming Huntington's readout could be its last, best hope at turning the ship around endpts.com/a-rare-neurolo…

Re-upping my piece from last week on a potential FDA commissioner under an RFK Jr.-led HHS

Biotech industry worries over potential for RFK Jr. ally as FDA pick endpts.com/biotech-indust…

Two outstanding pieces by @kakape on misinformation, open-access, @ScienceMagazine science.org/content/articl… science.org/content/articl…

Hints of impatience grow with Biogen as it tries to find a bridge to growth endpts.com/biogen-seeks-g…

What would RFK Jr. do on healthcare? Trump ally's FDA plans raise alarm - endpts.com/what-would-rfk…

NEW: Eli Lilly says a slightly tweaked dosing regimen of its Alzheimer's drug Kisunla can lower the rate of brain swelling side effects endpts.com/in-bid-to-lowe…

Evergreen reminder to always double check who you’re emailing before hitting send Ex-Pfizer CFO emailed CEO Albert Bourla over the weekend. The message was blank. But the “to” field included a rep for activist Starboard From @ArmstrongDrew @maxonwifi endpts.com/behind-the-sce…

This year’s Women in Biopharma R&D report is dedicated to Natalie Grover, who launched the project with @AmberTongPW in 2019 while they were working at Endpoints. We’re proud to continue their tradition of honoring 20 exceptional women leaders. endpts.com/special-report…

FDA approves first new schizophrenia drug in decades --> drug was centerpiece of Bristol Myers Squibb's $14B buyout of Karuna $BMY endpts.com/fda-approves-b…

The Federal Reserve cut interest rates by 50 bps. What does that mean for biotech, pharma and venture capital? endpts.com/what-does-toda…